GlobeNewswire by notified

NetSfere and Deutsche Telekom Partner to Deliver a Compliant Mobile Messaging Platform Enabling Instantaneous, Secure Staff Communication for Germany’s St. Augustinus Group

Share

The companies deployed the HIPAA/GDPR compliant encrypted messaging platform to stop the use of consumer-grade messaging apps and streamline internal and patient communications

CHICAGO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- NetSfere, a global provider of next-generation secure and compliant messaging and mobility solutions, today announces its partnership with Deutsche Telekom, one of the world’s leading integrated telecommunications companies, to deploy NetSfere’s secure mobile messaging platform in all St. Augustinus hospitals, a leading German healthcare group.

Quick, instantaneous communication tools offer undisputed benefits to streamline staff communication, however, St. Augustinus noticed an alarming increase in the use of personal devices and popular messaging apps like WhatsApp, which pose critical privacy and compliance risks. In response, NetSfere and Deutsche Telekom partnered to implement NetSfere’s HIPAA and GDPR compliant messaging platform that offers similar functionality to apps like WhatsApp but provides the highest level of end-to-end encryption through Deutsche Telekom’s highly secure data center.

"NetSfere is designed to meet security and compliance requirements in regulated verticals including healthcare," says Franz Obermayer, NetSfere's Vice President Europe. "Medical professionals do high-pressure, life-changing work, which demands a communication platform that enables them to do so more effectively. Our partnership with the St. Augustinus Group provides secure, compliant, and flexible messaging options that eliminate the need for staff members to turn to risky messaging apps. With NetSfere, the exchange of patient data is protected to the maximum."

Unlike consumer-grade messaging apps, NetSfere provides enterprise-grade functionalities that boost collaboration and streamline communications including individual and group messaging, HD audio calling, screen sharing, and group video calling. New to the platform, the NetSfere Lifeline emergency broadcast feature allows HR and crisis teams to quickly disseminate high priority, critical alerts and emergency information to targeted teams or an entire organization in an attention-grabbing manner. St. Augustinus is leveraging NetSfere broadcasting within its hospital to keep employees up-to-date on information related to the pandemic through its “Corona Ticker” NetSfere Lifeline channel.

"In the sensitive medical environment, it must be possible to communicate quickly and securely. NetSfere is the specialist for instant messages in companies. Telekom brings its expertise in security, consulting, and service. Together, we can meet the special industry requirements, and that is quite crucial right now," says Hagen Rickmann, Managing Director Business Customers, Telekom Deutschland GmbH. "In this way, we can directly contribute to relieving the burden on staff and support optimal patient care."

“It is our responsibility to equip our employees with suitable tools. They must be able to do their work effectively. At the same time, the privacy of our patients must be protected," says Rainer Pappert, Managing Director of the St. Augustinus Group. "With the introduction of NetSfere, we followed the wishes of our employees: They want to use their personal devices. And they want to do so with an easy-to-use messaging app. So, we quickly introduced NetSfere for internal communication. With it, we quickly achieved better productivity and collaboration. Between teams, but also within our entire group. And that's about 5,600 colleagues."

St. Augustinus was drawn to using NetSfere as a solution for its staff not only because of its robust functionality, but also its industry recognition. In 2018 and 2019, NetSfere was selected by Entscheiderfabrik, a platform for IT decision makers of over 800 German hospitals, as the winner of the “Digitization Topic of the German Healthcare Industry.”

“Key highlights from our recently published VoTE: Digital Pulse, Business Reinvention & Transformation 2021 show that information security, employee productivity and business continuity remain top of mind for IT decision-makers,” said Raúl Castañón-Martinez, Senior Analyst for Workforce Collaboration at 451 Research, part of S&P Global Market Intelligence division. These factors will drive market requirements for business communications and collaboration, particularly for mobile, remote/hybrid and frontline workers across verticals and use cases such as field workers and healthcare providers.”(1)

For more information, visit www.netsfere.com.

1. 451 Research, part of S&P Global Market Intelligence division, “The hybrid workplace, Part 3: Emerging requirements and use cases for real-time communications and collaboration” (August 2021)

About NetSfere
NetSfere is a secure enterprise messaging service and platform from Infinite Convergence Solutions, Inc. NetSfere provides industry-leading security and message delivery capabilities, including global cloud-based service availability, device-to-device encryption, location-based features and administrative controls. The service is also offered in partnership with Deutsche Telekom GmbH, one of the world’s leading integrated telecommunications companies, and with NTT Ltd., a global information communications & technology service provider, to jointly offer NetSfere to its worldwide customers. The service leverages Infinite Convergence's experience in delivering mobility solutions to tier 1 mobile operators globally and technology that supports more than 400 million subscribers and over a trillion messages on an annual basis. NetSfere is also compliant with global regulatory requirements, including GDPR, HIPAA, Sarbanes-Oxley, ISO 27001 and others. Infinite Convergence Solutions has offices in the United States, Germany, India and Singapore. For more information, visit www.netsfere.com.

About Deutsche Telekom
Deutsche Telekom is one of the world's leading integrated telecommunications companies, with some 242 million mobile customers, 27 million fixed-network lines, and 22 million broadband lines. We provide fixed-network/broadband, mobile communications, Internet, and IPTV products and services for consumers, and information and communication technology (ICT) solutions for business and corporate customers. Deutsche Telekom is present in more than 50 countries. With a staff of some 226,300 (Dec 31, 2020) employees throughout the world, we generated revenue of 101 billion Euros in the 2020 financial year, about 66 percent of it outside Germany.

About St. Augustinus Group
The Christian non-profit St. Augustinus Group is one of the largest and most successful companies in the health and social sector in the Rhineland. Its focus is on somatics, psychiatry, and elderly and disabled assistance. The group has 3,000 beds, over 5,600 employees from 68 nationalities, in 85 locations and a turnover of around 345 million euros (2019).

Media Contact
Brittany Johnson
Uproar PR for NetSfere
bjohnson@uproarpr.com
312-878-4575 x246

A video accompanying this release is available at: 

https://www.globenewswire.com/NewsRoom/AttachmentNg/d49c9ba2-b23b-490d-8c39-7cf18d6933df

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)16.4.2024 23:30:00 CEST | Press release

SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva SELARSDI is expected to be marketed in the U.S. on or after February 21, 2025, following a settlement agreement with Johnson & Johnson, the manufacturer of StelaraSELARSDI was developed and is manufactured by Alvotech using murine cell (Sp2/0) and a continuous perfusion process, which are the same type of cells and process used for the production of Stelara REYKJAVIK, ICELAND & PARSIPPANY, NJ — Alvotech (NASDAQ: ALVO) and Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced that the U.S. Food and Drug Administration (FDA) has approved SELARSDI (ustekinumab-aekn) injection for subcutaneous use, as a biosimilar to Stelara®, for the treatment of moderate to severe plaque psoriasis and for active psoriatic arthritis in adults and pediatric patients 6 years and older. Unde

Atico Reports Consolidated Financial Results for 202316.4.2024 22:30:29 CEST | Press release

(All amounts expressed in US dollars, unless otherwise stated) VANCOUVER, British Columbia, April 16, 2024 (GLOBE NEWSWIRE) -- Atico Mining Corporation (the “Company” or “Atico”) (TSX.V: ATY | OTC: ATCMF) today announced its financial results for the year ended December 31, 2023, posting income from mining operations of $7.4 million and a net loss of $5.8 million. Production for the year at Atico’s El Roble mine totaled 13.2 million pounds (“lbs”) of copper and 10,149 ounces (“oz”) of gold in concentrate at a cash cost(1) of $2.04 per payable pound of copper(2). Fernando E. Ganoza, CEO and Director, commented, "we had a challenging year overall, with the first half of the year facing lower than expected head grades and lower throughput due to mechanical and operational issues, coupled with a significant appreciation in the Colombian Peso throughout the year which materially increased our costs. Despite these challenges the team did a great job getting El Roble mine back on track in the

Ultimovacs Implements Operational Adjustments to Support Continuous Advancement of the UV1 Vaccine Phase II Program16.4.2024 22:10:00 CEST | Press release

Due to the broad diversity in the UV1 Phase II program and the encouraging results from previous UV1 trials, Ultimovacs remain confident in UV1’s potential and are strongly committed to bringing the company across the next important data points: The readout from FOCUS in Q3 2024 and DOVACC results in H1 2025Activity level adjustments and operational prioritization are implemented to sustain the financial runway, including a workforce reduction of approximately 40% The operational adjustment plan extends the anticipated cash runway to the fourth quarter of 2025, through the readout from the Phase II DOVACC trial Oslo, April 16, 2024: Ultimovacs ASA (“Ultimovacs”) (OSE ULTI), a clinical-stage biotechnology company developing immunotherapeutic cancer vaccines, today announces a plan to optimize its business operations to support the continuous advancement of UV1 and long-term business growth. “We remain dedicated to our investigation of the potential impact of UV1 vaccine across several c

ClearPoint Neuro Congratulates its Partner AviadoBio on First Patient Treated in its ASPIRE-FTD Clinical Trial Evaluating AVB-101 for Frontotemporal Dementia with GRN Mutations16.4.2024 22:05:00 CEST | Press release

ASPIRE-FTD Sites in the EU and U.S. to Use ClearPoint® Navigation Together With SmartFlow® Cannula for Intrathalamic Gene Therapy Administration SOLANA BEACH, Calif., April 16, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine, today congratulates its partner AviadoBio on treating its first patient in the ASPIRE-FTD Phase 1/2 clinical trial evaluating its investigational gene therapy AVB-101 in people with frontotemporal dementia (FTD) with progranulin (GRN) mutations. “FTD is an important cause of dementia in people under 65 and has a devastating impact on patients and families. The importance of accurately delivering this one-time gene therapy to the thalamus, while minimizing systemic exposure, is the precise use case of ClearPoint’s minimally invasive platform for gene and cell delivery,” stated Jeremy Stigall, Chief Business Officer at ClearPoin

Nokia Corporation: Repurchase of own shares on 16.04.202416.4.2024 21:30:00 CEST | Press release

Nokia Corporation Stock Exchange Release 16 April 2024 at 22:30 EEST Nokia Corporation: Repurchase of own shares on 16.04.2024 Espoo, Finland – On 16 April 2024 Nokia Corporation (LEI: 549300A0JPRWG1KI7U06) has acquired its own shares (ISIN FI0009000681) as follows: Trading venue (MIC Code)Number of sharesWeighted average price / share, EUR*XHEL557,6403.17CEUX--BATE--AQEU--TQEX--Total557,6403.17 * Rounded to two decimals On 25 January 2024, Nokia announced that its Board of Directors is initiating a share buyback program to return up to EUR 600 million of cash to shareholders in tranches over a period of two years. The first phase of the share buyback program in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR), the Commission Delegated Regulation (EU) 2016/1052 and under the authorization granted by Nokia’s Annual General Meeting on 4 April 2023 started on 20 March 2024 and ends by 18 December 2024 with a maximum aggregate purchase price of EUR 300 million. Total cost of

HiddenA line styled icon from Orion Icon Library.Eye